Literature DB >> 26032638

Biosynthesis and actions of 5-oxoeicosatetraenoic acid (5-oxo-ETE) on feline granulocytes.

Chantal Cossette1, Sylvie Gravel2, Chintam Nagendra Reddy3, Vivek Gore4, Shishir Chourey5, Qiuji Ye6, Nathaniel W Snyder7, Clementina A Mesaros8, Ian A Blair9, Jean-Pierre Lavoie10, Carol R Reinero11, Joshua Rokach12, William S Powell13.   

Abstract

The 5-lipoxygenase product 5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) is the most powerful human eosinophil chemoattractant among lipid mediators and could play a major pathophysiological role in eosinophilic diseases such as asthma. Its actions are mediated by the OXE receptor, orthologs of which are found in many species from humans to fish, but not rodents. The unavailability of rodent models to examine the pathophysiological roles of 5-oxo-ETE and the OXE receptor has substantially hampered progress in this area. As an alternative, we have explored the possibility that the cat could serve as an appropriate animal model to investigate the role of 5-oxo-ETE. We found that feline peripheral blood leukocytes synthesize 5-oxo-ETE and that physiologically relevant levels of 5-oxo-ETE are present in bronchoalveolar lavage fluid from cats with experimentally induced asthma. 5-Oxo-ETE (EC50, 0.7nM) is a much more potent activator of actin polymerization in feline eosinophils than various other eicosanoids, including leukotriene (LT) B4 and prostaglandin D2. 5-Oxo-ETE and LTB4 induce feline leukocyte migration to similar extents at low concentrations (1nM), but at higher concentrations the response to 5-oxo-ETE is much greater. Although high concentrations of selective human OXE receptor antagonists blocked 5-oxo-ETE-induced actin polymerization in feline granulocytes, their potencies were about 200 times lower than for human granulocytes. We conclude that feline leukocytes synthesize and respond to 5-oxo-ETE, which could potentially play an important role in feline asthma, a common condition in this species. The cat could serve as a useful animal model to investigate the pathophysiological role of 5-oxo-ETE.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  5-Lipoxygenase; Eicosanoids; Eosinophils; Inflammation; Neutrophils; OXE receptor

Mesh:

Substances:

Year:  2015        PMID: 26032638      PMCID: PMC4830392          DOI: 10.1016/j.bcp.2015.05.009

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  40 in total

1.  Precolumn extraction and reversed-phase high-pressure liquid chromatography of prostaglandins and leukotrienes.

Authors:  W S Powell
Journal:  Anal Biochem       Date:  1987-07       Impact factor: 3.365

2.  On the specificity of the oxygenation of unsaturated fatty acids catalyzed by soybean lipoxidase.

Authors:  M Hamberg; B Samuelsson
Journal:  J Biol Chem       Date:  1967-11-25       Impact factor: 5.157

3.  TG1019/OXE, a Galpha(i/o)-protein-coupled receptor, mediates 5-oxo-eicosatetraenoic acid-induced chemotaxis.

Authors:  Takeshi Hosoi; Emiko Sugikawa; Aiko Chikada; Yutaka Koguchi; Tetsuo Ohnuki
Journal:  Biochem Biophys Res Commun       Date:  2005-09-09       Impact factor: 3.575

4.  Metabolism of 5(S)-hydroxy-6,8,11,14-eicosatetraenoic acid and other 5(S)-hydroxyeicosanoids by a specific dehydrogenase in human polymorphonuclear leukocytes.

Authors:  W S Powell; F Gravelle; S Gravel
Journal:  J Biol Chem       Date:  1992-09-25       Impact factor: 5.157

5.  Stimulation of human neutrophils by 5-oxo-6,8,11,14-eicosatetraenoic acid by a mechanism independent of the leukotriene B4 receptor.

Authors:  W S Powell; S Gravel; R J MacLeod; E Mills; M Hashefi
Journal:  J Biol Chem       Date:  1993-05-05       Impact factor: 5.157

6.  5-Oxo-eicosatetraenoate, a potent human neutrophil stimulus.

Authors:  J T O'Flaherty; J Cordes; J Redman; M J Thomas
Journal:  Biochem Biophys Res Commun       Date:  1993-04-15       Impact factor: 3.575

7.  Metabolism and biologic effects of 5-oxoeicosanoids on human neutrophils.

Authors:  W S Powell; R J MacLeod; S Gravel; F Gravelle; A Bhakar
Journal:  J Immunol       Date:  1996-01-01       Impact factor: 5.422

8.  Effects of phorbol myristate acetate on the synthesis of 5-oxo-6,8,11,14-eicosatetraenoic acid by human polymorphonuclear leukocytes.

Authors:  W S Powell; Y Zhang; S Gravel
Journal:  Biochemistry       Date:  1994-04-05       Impact factor: 3.162

9.  Free radical production from the aerobic oxidation of reduced pyridine nucleotides catalysed by phenazine derivatives.

Authors:  G Davis; P J Thornalley
Journal:  Biochim Biophys Acta       Date:  1983-09-30

10.  5-Oxo-eicosanoids are potent eosinophil chemotactic factors. Functional characterization and structural requirements.

Authors:  U Schwenk; J M Schröder
Journal:  J Biol Chem       Date:  1995-06-23       Impact factor: 5.157

View more
  7 in total

1.  In vivo α-hydroxylation of a 2-alkylindole antagonist of the OXE receptor for the eosinophil chemoattractant 5-oxo-6,8,11,14-eicosatetraenoic acid in monkeys.

Authors:  Shishir Chourey; Qiuji Ye; Chintam Nagendra Reddy; Chantal Cossette; Sylvie Gravel; Matthias Zeller; Irina Slobodchikova; Dajana Vuckovic; Joshua Rokach; William S Powell
Journal:  Biochem Pharmacol       Date:  2017-05-03       Impact factor: 5.858

2.  Targeting the OXE receptor with a selective antagonist inhibits allergen-induced pulmonary inflammation in non-human primates.

Authors:  Chantal Cossette; Lisa A Miller; Qiuji Ye; Shishir Chourey; Chintam Nagendra Reddy; Joshua Rokach; William S Powell
Journal:  Br J Pharmacol       Date:  2021-12-16       Impact factor: 8.739

3.  Inhibition of allergen-induced dermal eosinophilia by an oxoeicosanoid receptor antagonist in non-human primates.

Authors:  Lisa A Miller; Chantal Cossette; Shishir Chourey; Qiuji Ye; Chintam Nagendra Reddy; Joshua Rokach; William S Powell
Journal:  Br J Pharmacol       Date:  2020-01-17       Impact factor: 8.739

4.  Novel highly potent OXE receptor antagonists with prolonged plasma lifetimes that are converted to active metabolites in vivo in monkeys.

Authors:  Qiuji Ye; Shishir Chourey; Chintam Nagendra Reddy; Rui Wang; Chantal Cossette; Sylvie Gravel; Irina Slobodchikova; Dajana Vuckovic; Joshua Rokach; William S Powell
Journal:  Br J Pharmacol       Date:  2020-01-17       Impact factor: 8.739

Review 5.  Eicosanoid Mediators in the Airway Inflammation of Asthmatic Patients: What is New?

Authors:  Marek Sanak
Journal:  Allergy Asthma Immunol Res       Date:  2016-11       Impact factor: 5.764

6.  5-Lipooxygenase Derivatives as Serum Biomarkers of a Successful Dietary Intervention in Patients with NonAlcoholic Fatty Liver Disease.

Authors:  Marcin Banaszczak; Dominika Maciejewska; Arleta Drozd; Karina Ryterska; Dominika Jamioł Milc; Joanna Raszeja-Wyszomirska; Ewa Wunsch; Pedro González-Muniesa; Ewa Stachowska
Journal:  Medicina (Kaunas)       Date:  2020-02-03       Impact factor: 2.430

7.  Eicosanoids metabolized through LOX distinguish asthma-COPD overlap from COPD by metabolomics study.

Authors:  Chuanxu Cai; Xiqing Bian; Mingshan Xue; Xiaoqing Liu; Haisheng Hu; Jingxian Wang; Song Guo Zheng; Baoqing Sun; Jian-Lin Wu
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-08-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.